Recoveries and Settlements
$1.6 Billion Settlement from Bayer HealthCare
G&E principals currently serve on Plaintiffs’ Leadership and helped reach a $1.6 billion settlement on behalf of thousands of women impacted by permanent contraceptive device Essure, including the almost 2,000 clients represented individually by G&E.
$1.4 Billion Settlement from Stryker Corporation
Stryker Corporation paid $1.4 billion to compensate approximately 4,000 patients forced to replace their Rejuvenate and ABG II implants after the devices failed.
$775 Million Settlement with Bayer HealthCare and Janssen Pharmaceuticals
G&E principals held leadership positions on the Plaintiffs’ Steering Committee in litigation concerning dangerous side-effects of the anti-coagulant drug Xarelto.
Confidential Settlement with Stryker in LFIT V40 Hip Implant Case
G&E served on the Plaintiffs’ Steering Committee in the MDL concerning alleged defects in Stryker-branded LFIT Anatomic CoCR V40 femoral heads, a prosthetic hip replacement device.
Confidential Settlement with Ethicon in Power Morcellators Case
G&E principals served on the Plaintiffs’ Steering Committee in the MDL concerning power morcellators, small medical devices used in fibroid surgery, that spread undetected uterine cancers.
Other Pharmaceutical Recoveries
$2.3 Billion Settlement from Pfizer
G&E’s False Claims Litigation Group represented one of six whistleblowers who revealed information to the government that resulted in an overall $2.3 billion recovery for the federal and state governments.
$1.6 Billion Settlement from Abbott Laboratories
G&E’s efforts on behalf of the lead whistleblower against Abbott Laboratories served as a catalyst for a $1.6 billion recovery for federal and state governments. The case concerned unlawful marketing of Abbott’s anti-epileptic drug Depakote.
$1.04 Billion Settlement from GlaxoSmithKline
G&E represented one of several whistleblowers that resulted in a $1.04 billion recovery for the federal and state governments. The suit arose from alleged misrepresentation by GlaxoSmithKline in its promotion of drug Advair.
$922 Million Settlement from UnitedHealth Group
G&E served as co-lead counsel in a derivative and class action suit successfully challenging $1.2 billion in back-dated options granted to then-CEO of health care provider UnitedHealth Group. The $922 million settlement is the largest settlement in the history of derivative litigation in any jurisdiction.
$486 Million Settlement from Pfizer
G&E was lead counsel in a securities class action against Pfizer concerning its multi-billion-dollar arthritis drugs, Celebrex and Bextra. Plaintiffs alleged that Pfizer misrepresented the cardiovascular safety of the drugs.
$257.4 Million Settlement from Wyeth Pharmaceuticals
G&E represented two key whistleblowers behind a $257.4 million settlement between drugmaker Wyeth Pharmaceuticals and the U.S. Department of Justice stemming from alleged marketing abuses of Wyeth’s powerful immunosuppressant drug Rapamune.
$215 Million Settlement from Merck & Co.
G&E served as co-lead counsel in a securities class action settlement against Merck after the drugmaker’s stock price plummeted and shareholders lost billions of dollars. The case related to the company’s anti-cholesterol drug, Vytorin.
$175 Million Settlement from McKesson
One of the largest derivative case settlements was reached in 2020, concerning failures of Board oversight at McKesson. The case related to the company’s role in the increase of opioid drug abuse in the United States.
$52 Million Settlement from Abbott Laboratories
G&E achieved a major settlement on behalf of purchasers of anti-HIV medicines in an antitrust class action.
$41.5 Million Settlement from Merck
As consumer subclass counsel and member of the steering committee, G&E attorneys obtained a $41.5 million recovery on behalf of consumers who overpaid for Merck Vytorin and Zetia, which defendants deceptively marketed as being more effective than other anti-cholesterol drugs.
$25 Million Settlement from Pfizer
G&E represented the Attorney General for the State of Mississippi in litigation against pharmaceutical manufacturer GlaxoSmithKline for claims arising out of the company’s misleading marketing and promotion of nine drugs, including blockbuster products Paxil, Wellbutrin, Advair, and Zofran.
$24.9 Million settlement from Amgen, Inc.
In a major whistleblower settlement, G&E, working with the U.S. Department of Justice and the U.S. Attorney’s office in South Carolina, reached an agreement with Amgen resolving claims that it paid kickbacks to long-term care pharmacies so that elderly patients in nursing homes across the nation would be switched to or placed on the company’s drug, Aranesp.